Advertisement
Advertisement

TVTX

TVTX logo

Travere Therapeutics Inc

17.12
USD
-0.38
-2.17%
Dec 17, 15:59 UTC -5
Closed
...

Travere Therapeutics Inc Profile

About

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

Info & Links

CEO

Eric Dube

Headquarters

3611 VALLEY CENTRE DR, SUITE 300
SAN DIEGO, CA 92130, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

175

Employees

380

Travere Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

1.34B

Enterprise Value

1.68B

Enterprise Value/EBITDA(ttm)

-5.21

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

6.64

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

94.96%

Operating Margin(ttm)

-171.52%

Profit Margin(ttm)

-186.56%

Return on Equity(ttm)

-537.74%

Return on Invested Capital(ttm)

-82.72%

Return on Assets(ttm)

-55.65%

Income Statement

Revenue(ttm)

203.45M

Revenue Per Share(ttm)

2.61

Gross Profit(ttm)

193.69M

EBITDA(ttm)3

-322.11M

Net Income Available to Common(ttm)

-351.45M

Diluted EPS(ttm)

-4.55

Share Statistics

Beta (5Y Monthly)

0.69

52-Week Change

172.18%

S&P 500 52-Week Change

27.63%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

78.05M

Dividend Yield

0.00%

Float4

74.88M

% Held by Insiders

4.06%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

277.44M

Total Cash Per Share(mrq)

3.55

Total Debt(mrq)

378.56M

Total Debt/Equity(mrq)

-1243.04%

Current Ratio(mrq)

1.71%

Quick Ratio(mrq)

1.68%

Book Value Per Share(mrq)

-0.39

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.59

Free Cash Flow(ytd)

-201.84M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement